1 Report Overview 1.1 Research Scope 1.2 Market Segment by Type 1.2.1 Global Myasthenia Gravis Drugs Market Size Growth Rate by Type (2017 VS 2021 VS 2028) 1.2.2 Anticholinesterases 1.2.3 Immunosuppressants 1.2.4 Intravenous Immune Globulins 1.3 Market Segment by Application 1.3.1 Global Myasthenia Gravis Drugs Market Share by Application (2017 VS 2021 VS 2028) 1.3.2 Hospitals 1.3.3 Clinics 1.4 Study Objectives 1.5 Years Considered 2 Market Perspective 2.1 Global Myasthenia Gravis Drugs Market Size (2017-2028) 2.1.1 Global Myasthenia Gravis Drugs Revenue (2017-2028) 2.1.2 Global Myasthenia Gravis Drugs Sales (2017-2028) 2.2 Global Myasthenia Gravis Drugs Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028 2.2.1 Global Myasthenia Gravis Drugs Sales by Regions (2017-2022) 2.2.2 Global Myasthenia Gravis Drugs Revenue by Regions (2017-2022) 2.3 Global Myasthenia Gravis Drugs Market Size Forecast by Region 2.3.1 Global Myasthenia Gravis Drugs Sales Forecast by Region (2023-2028) 2.3.2 Global Myasthenia Gravis Drugs Revenue Forecast by Region (2023-2028) 2.4 Global Top Myasthenia Gravis Drugs Regions (Countries) Ranking by Market Size 2.5 Myasthenia Gravis Drugs Market Dynamics 2.5.1 Myasthenia Gravis Drugs Market Trends 2.5.2 Myasthenia Gravis Drugs Market Drivers 2.5.3 Myasthenia Gravis Drugs Market Challenges 2.5.4 Myasthenia Gravis Drugs Market Restraints 3 Competitive Landscape by Manufacturers 3.1 Global Top Myasthenia Gravis Drugs Manufacturers by Sales (2017-2022) 3.1.1 Global Myasthenia Gravis Drugs Sales by Manufacturers (2017-2022) 3.1.2 Global Myasthenia Gravis Drugs Sales Market Share by Manufacturers (2017-2022) 3.1.3 Global 5 and 10 Largest Manufacturers by Myasthenia Gravis Drugs Sales in 2021 3.2 Global Top Manufacturers Myasthenia Gravis Drugs by Revenue 3.2.1 Global Myasthenia Gravis Drugs Revenue by Manufacturers (2017-2022) 3.2.2 Top Myasthenia Gravis Drugs Manufacturers Covered: Ranking by Revenue 3.2.3 Global Myasthenia Gravis Drugs Revenue Share by Manufacturers (2017-2022) 3.2.4 Global Myasthenia Gravis Drugs Market Concentration Ratio (CR5 and HHI) 3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Myasthenia Gravis Drugs as of 2021) 3.4 Global Myasthenia Gravis Drugs Average Selling Price (ASP) by Manufacturers 3.5 Key Manufacturers Myasthenia Gravis Drugs Plants/Factories Distribution and Area Served 3.6 Date of Key Manufacturers Enter into Myasthenia Gravis Drugs Market 3.7 Key Manufacturers Myasthenia Gravis Drugs Product Offered 3.8 Mergers & Acquisitions, Expansion Plans 4 Global Myasthenia Gravis Drugs Market Size by Type 4.1 Global Myasthenia Gravis Drugs Historic Market Review by Type (2017-2022) 4.1.1 Global Myasthenia Gravis Drugs Sales Market Share by Type (2017-2022) 4.1.2 Global Myasthenia Gravis Drugs Revenue Market Share by Type (2017-2022) 4.1.3 Myasthenia Gravis Drugs Price by Type (2017-2022) 4.2 Global Myasthenia Gravis Drugs Market Estimates and Forecasts by Type (2023-2028) 4.2.1 Global Myasthenia Gravis Drugs Sales Forecast by Type (2023-2028) 4.2.2 Global Myasthenia Gravis Drugs Revenue Forecast by Type (2023-2028) 4.2.3 Myasthenia Gravis Drugs Price Forecast by Type (2023-2028) 5 Global Myasthenia Gravis Drugs Market Size by Application 5.1 Global Myasthenia Gravis Drugs Historic Market Review by Application (2017-2022) 5.1.1 Global Myasthenia Gravis Drugs Sales Market Share by Application (2017-2022) 5.1.2 Global Myasthenia Gravis Drugs Revenue Market Share by Application (2017-2022) 5.1.3 Myasthenia Gravis Drugs Price by Application (2017-2022) 5.2 Global Myasthenia Gravis Drugs Market Estimates and Forecasts by Application (2023-2028) 5.2.1 Global Myasthenia Gravis Drugs Sales Forecast by Application (2023-2028) 5.2.2 Global Myasthenia Gravis Drugs Revenue Forecast by Application (2023-2028) 5.2.3 Myasthenia Gravis Drugs Price Forecast by Application (2023-2028) 6 North America 6.1 North America Myasthenia Gravis Drugs Sales Breakdown by Company 6.1.1 North America Myasthenia Gravis Drugs Sales by Company (2017-2022) 6.1.2 North America Myasthenia Gravis Drugs Revenue by Company (2017-2022) 6.2 North America Myasthenia Gravis Drugs Market Size by Type 6.2.1 North America Myasthenia Gravis Drugs Sales by Type (2017-2028) 6.2.2 North America Myasthenia Gravis Drugs Revenue by Type (2017-2028) 6.3 North America Myasthenia Gravis Drugs Market Size by Application 6.3.1 North America Myasthenia Gravis Drugs Sales by Application (2017-2028) 6.3.2 North America Myasthenia Gravis Drugs Revenue by Application (2017-2028) 6.4 North America Myasthenia Gravis Drugs Market Size by Country 6.4.1 North America Myasthenia Gravis Drugs Sales by Country (2017-2028) 6.4.2 North America Myasthenia Gravis Drugs Revenue by Country (2017-2028) 6.4.3 U.S. 6.4.4 Canada 7 Europe 7.1 Europe Myasthenia Gravis Drugs Sales Breakdown by Company 7.1.1 Europe Myasthenia Gravis Drugs Sales by Company (2017-2022) 7.1.2 Europe Myasthenia Gravis Drugs Revenue by Company (2017-2022) 7.2 Europe Myasthenia Gravis Drugs Market Size by Type 7.2.1 Europe Myasthenia Gravis Drugs Sales by Type (2017-2028) 7.2.2 Europe Myasthenia Gravis Drugs Revenue by Type (2017-2028) 7.3 Europe Myasthenia Gravis Drugs Market Size by Application 7.3.1 Europe Myasthenia Gravis Drugs Sales by Application (2017-2028) 7.3.2 Europe Myasthenia Gravis Drugs Revenue by Application (2017-2028) 7.4 Europe Myasthenia Gravis Drugs Market Size by Country 7.4.1 Europe Myasthenia Gravis Drugs Sales by Country (2017-2028) 7.4.2 Europe Myasthenia Gravis Drugs Revenue by Country (2017-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 8 Asia Pacific 8.1 Asia Pacific Myasthenia Gravis Drugs Sales Breakdown by Company 8.1.1 Asia Pacific Myasthenia Gravis Drugs Sales by Company (2017-2022) 8.1.2 Asia Pacific Myasthenia Gravis Drugs Revenue by Company (2017-2022) 8.2 Asia Pacific Myasthenia Gravis Drugs Market Size by Type 8.2.1 Asia Pacific Myasthenia Gravis Drugs Sales by Type (2017-2028) 8.2.2 Asia Pacific Myasthenia Gravis Drugs Revenue by Type (2017-2028) 8.3 Asia Pacific Myasthenia Gravis Drugs Market Size by Application 8.3.1 Asia Pacific Myasthenia Gravis Drugs Sales by Application (2017-2028) 8.3.2 Asia Pacific Myasthenia Gravis Drugs Revenue by Application (2017-2028) 8.4 Asia Pacific Myasthenia Gravis Drugs Market Size by Region 8.4.1 Asia Pacific Myasthenia Gravis Drugs Sales by Region 8.4.2 Asia Pacific Myasthenia Gravis Drugs Revenue by Region 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 India 8.4.7 Australia 8.4.8 Taiwan 8.4.9 Indonesia 8.4.10 Thailand 8.4.11 Malaysia 8.4.12 Philippines 8.4.13 Vietnam 9 Latin America 9.1 Latin America Myasthenia Gravis Drugs Sales Breakdown by Company 9.1.1 Latin America Myasthenia Gravis Drugs Sales by Company (2017-2022) 9.1.2 Latin America Myasthenia Gravis Drugs Revenue by Company (2017-2022) 9.2 Latin America Myasthenia Gravis Drugs Market Size by Type 9.2.1 Latin America Myasthenia Gravis Drugs Sales by Type (2017-2028) 9.2.2 Latin America Myasthenia Gravis Drugs Revenue by Type (2017-2028) 9.3 Latin America Myasthenia Gravis Drugs Market Size by Application 9.3.1 Latin America Myasthenia Gravis Drugs Sales by Application (2017-2028) 9.3.2 Latin America Myasthenia Gravis Drugs Revenue by Application (2017-2028) 9.4 Latin America Myasthenia Gravis Drugs Market Size by Country 9.4.1 Latin America Myasthenia Gravis Drugs Sales by Country (2017-2028) 9.4.2 Latin America Myasthenia Gravis Drugs Revenue by Country (2017-2028) 9.4.3 Mexico 9.4.4 Brazil 9.4.5 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Myasthenia Gravis Drugs Sales Breakdown by Company 10.1.1 Middle East and Africa Myasthenia Gravis Drugs Sales by Company (2017-2022) 10.1.2 Middle East and Africa Myasthenia Gravis Drugs Revenue by Company (2017-2022) 10.2 Middle East and Africa Myasthenia Gravis Drugs Market Size by Type 10.2.1 Middle East and Africa Myasthenia Gravis Drugs Sales by Type (2017-2028) 10.2.2 Middle East and Africa Myasthenia Gravis Drugs Revenue by Type (2017-2028) 10.3 Middle East and Africa Myasthenia Gravis Drugs Market Size by Application 10.3.1 Middle East and Africa Myasthenia Gravis Drugs Sales by Application (2017-2028) 10.3.2 Middle East and Africa Myasthenia Gravis Drugs Revenue by Application (2017-2028) 10.4 Middle East and Africa Myasthenia Gravis Drugs Market Size by Country 10.4.1 Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2017-2028) 10.4.2 Middle East and Africa Myasthenia Gravis Drugs Revenue by Country (2017-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 U.A.E 11 Company Profiles 11.1 Flamel Technologies 11.1.1 Flamel Technologies Corporation Information 11.1.2 Flamel Technologies Overview 11.1.3 Flamel Technologies Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.1.4 Flamel Technologies Myasthenia Gravis Drugs Products and Services 11.1.5 Flamel Technologies Myasthenia Gravis Drugs SWOT Analysis 11.1.6 Flamel Technologies Recent Developments 11.2 F. Hoffmann-La Roche 11.2.1 F. Hoffmann-La Roche Corporation Information 11.2.2 F. Hoffmann-La Roche Overview 11.2.3 F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.2.4 F. Hoffmann-La Roche Myasthenia Gravis Drugs Products and Services 11.2.5 F. Hoffmann-La Roche Myasthenia Gravis Drugs SWOT Analysis 11.2.6 F. Hoffmann-La Roche Recent Developments 11.3 Grifols 11.3.1 Grifols Corporation Information 11.3.2 Grifols Overview 11.3.3 Grifols Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.3.4 Grifols Myasthenia Gravis Drugs Products and Services 11.3.5 Grifols Myasthenia Gravis Drugs SWOT Analysis 11.3.6 Grifols Recent Developments 11.4 Pfizer 11.4.1 Pfizer Corporation Information 11.4.2 Pfizer Overview 11.4.3 Pfizer Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.4.4 Pfizer Myasthenia Gravis Drugs Products and Services 11.4.5 Pfizer Myasthenia Gravis Drugs SWOT Analysis 11.4.6 Pfizer Recent Developments 11.5 Takeda 11.5.1 Takeda Corporation Information 11.5.2 Takeda Overview 11.5.3 Takeda Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.5.4 Takeda Myasthenia Gravis Drugs Products and Services 11.5.5 Takeda Myasthenia Gravis Drugs SWOT Analysis 11.5.6 Takeda Recent Developments 11.6 Novartis 11.6.1 Novartis Corporation Information 11.6.2 Novartis Overview 11.6.3 Novartis Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.6.4 Novartis Myasthenia Gravis Drugs Products and Services 11.6.5 Novartis Myasthenia Gravis Drugs SWOT Analysis 11.6.6 Novartis Recent Developments 11.7 Bausch Health 11.7.1 Bausch Health Corporation Information 11.7.2 Bausch Health Overview 11.7.3 Bausch Health Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.7.4 Bausch Health Myasthenia Gravis Drugs Products and Services 11.7.5 Bausch Health Myasthenia Gravis Drugs SWOT Analysis 11.7.6 Bausch Health Recent Developments 11.8 Alexion Pharmaceuticals 11.8.1 Alexion Pharmaceuticals Corporation Information 11.8.2 Alexion Pharmaceuticals Overview 11.8.3 Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.8.4 Alexion Pharmaceuticals Myasthenia Gravis Drugs Products and Services 11.8.5 Alexion Pharmaceuticals Myasthenia Gravis Drugs SWOT Analysis 11.8.6 Alexion Pharmaceuticals Recent Developments 11.9 Catalyst Pharmaceuticals 11.9.1 Catalyst Pharmaceuticals Corporation Information 11.9.2 Catalyst Pharmaceuticals Overview 11.9.3 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.9.4 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Products and Services 11.9.5 Catalyst Pharmaceuticals Myasthenia Gravis Drugs SWOT Analysis 11.9.6 Catalyst Pharmaceuticals Recent Developments 11.10 CSL 11.10.1 CSL Corporation Information 11.10.2 CSL Overview 11.10.3 CSL Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.10.4 CSL Myasthenia Gravis Drugs Products and Services 11.10.5 CSL Myasthenia Gravis Drugs SWOT Analysis 11.10.6 CSL Recent Developments 11.11 Curavac 11.11.1 Curavac Corporation Information 11.11.2 Curavac Overview 11.11.3 Curavac Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.11.4 Curavac Myasthenia Gravis Drugs Products and Services 11.11.5 Curavac Recent Developments 11.12 Cytokinetics 11.12.1 Cytokinetics Corporation Information 11.12.2 Cytokinetics Overview 11.12.3 Cytokinetics Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.12.4 Cytokinetics Myasthenia Gravis Drugs Products and Services 11.12.5 Cytokinetics Recent Developments 11.13 Galencia 11.13.1 Galencia Corporation Information 11.13.2 Galencia Overview 11.13.3 Galencia Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.13.4 Galencia Myasthenia Gravis Drugs Products and Services 11.13.5 Galencia Recent Developments 11.14 GlaxoSmithKline 11.14.1 GlaxoSmithKline Corporation Information 11.14.2 GlaxoSmithKline Overview 11.14.3 GlaxoSmithKline Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.14.4 GlaxoSmithKline Myasthenia Gravis Drugs Products and Services 11.14.5 GlaxoSmithKline Recent Developments 11.15 Lupin Pharmaceuticals 11.15.1 Lupin Pharmaceuticals Corporation Information 11.15.2 Lupin Pharmaceuticals Overview 11.15.3 Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.15.4 Lupin Pharmaceuticals Myasthenia Gravis Drugs Products and Services 11.15.5 Lupin Pharmaceuticals Recent Developments 11.16 Mitsubishi Tanabe Pharma 11.16.1 Mitsubishi Tanabe Pharma Corporation Information 11.16.2 Mitsubishi Tanabe Pharma Overview 11.16.3 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.16.4 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Products and Services 11.16.5 Mitsubishi Tanabe Pharma Recent Developments 12 Value Chain and Sales Channels Analysis 12.1 Myasthenia Gravis Drugs Value Chain Analysis 12.2 Myasthenia Gravis Drugs Key Raw Materials 12.2.1 Key Raw Materials 12.2.2 Raw Materials Key Suppliers 12.3 Myasthenia Gravis Drugs Production Mode & Process 12.4 Myasthenia Gravis Drugs Sales and Marketing 12.4.1 Myasthenia Gravis Drugs Sales Channels 12.4.2 Myasthenia Gravis Drugs Distributors 12.5 Myasthenia Gravis Drugs Customers 13 Research Findings and Conclusion 14 Appendix 14.1 Research Methodology 14.1.1 Methodology/Research Approach 14.1.2 Data Source 14.2 Author Details 14.3 Disclaimer

List of Tables Table 1. Global Myasthenia Gravis Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million) Table 2. Major Manufacturers of Anticholinesterases Table 3. Major Manufacturers of Immunosuppressants Table 4. Major Manufacturers of Intravenous Immune Globulins Table 5. Global Myasthenia Gravis Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million) Table 6. Global Myasthenia Gravis Drugs Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028 Table 7. Global Myasthenia Gravis Drugs Sales by Region (2017-2022) & (MT) Table 8. Global Myasthenia Gravis Drugs Sales Market Share by Region (2017-2022) Table 9. Global Myasthenia Gravis Drugs Revenue by Region (2017-2022) & (US$ Million) Table 10. Global Myasthenia Gravis Drugs Revenue Market Share by Region (2017-2022) Table 11. Global Myasthenia Gravis Drugs Sales Forecast by Region (2023-2028) & (MT) Table 12. Global Myasthenia Gravis Drugs Sales Market Share Forecast by Region (2023-2028) Table 13. Global Myasthenia Gravis Drugs Revenue Forecast by Region (2023-2028) & (US$ Million) Table 14. Global Myasthenia Gravis Drugs Revenue Market Share Forecast by Region (2023-2028) Table 15. Top Myasthenia Gravis Drugs Regions (Countries) Ranking by Market Size (US$ Million) in 2021 Table 16. Myasthenia Gravis Drugs Market Trends Table 17. Myasthenia Gravis Drugs Market Drivers Table 18. Myasthenia Gravis Drugs Market Challenges Table 19. Myasthenia Gravis Drugs Market Restraints Table 20. Global Myasthenia Gravis Drugs Sales by Manufacturers (2017-2022) & (MT) Table 21. Global Myasthenia Gravis Drugs Sales Share by Manufacturers (2017-2022) Table 22. Global Myasthenia Gravis Drugs Revenue by Manufacturers (2017-2022) & (US$ Million) Table 23. Ranking of Global Top Myasthenia Gravis Drugs Manufacturers by Revenue (US$ Million) in 2021 Table 24. Myasthenia Gravis Drugs Revenue Share by Manufacturers (2017-2022) Table 25. Global Myasthenia Gravis Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) Table 26. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Myasthenia Gravis Drugs as of 2021) Table 27. Key Manufacturers Myasthenia Gravis Drugs Average Selling Price (ASP) & (2017-2022) & (USD/Kg) Table 28. Key Manufacturers Myasthenia Gravis Drugs Plants/Factories Distribution Table 29. Key Manufacturers Myasthenia Gravis Drugs Area Served Table 30. Date of Key Manufacturers Enter into Myasthenia Gravis Drugs Market Table 31. Key Manufacturers Myasthenia Gravis Drugs Product Type Table 32. Mergers & Acquisitions, Expansion Plans Table 33. Global Myasthenia Gravis Drugs Sales (MT) by Type (2017-2022) Table 34. Global Myasthenia Gravis Drugs Sales Share by Type (2017-2022) Table 35. Global Myasthenia Gravis Drugs Revenue (US$ Million) Market Share by Type (2017-2022) Table 36. Global Myasthenia Gravis Drugs Price (MT) by Type (2017-2022) Table 37. Global Myasthenia Gravis Drugs Sales (MT) by Type (2023-2028) Table 38. Global Myasthenia Gravis Drugs Sales Share by Type (2023-2028) Table 39. Global Myasthenia Gravis Drugs Revenue (US$ Million) Market Share by Type (2023-2028) Table 40. Global Myasthenia Gravis Drugs Revenue Share by Type (2023-2028) Table 41. Global Myasthenia Gravis Drugs Price (MT) by Type (2023-2028) Table 42. Global Myasthenia Gravis Drugs Sales (MT) by Application (2017-2022) Table 43. Global Myasthenia Gravis Drugs Sales Share by Application (2017-2022) Table 44. Global Myasthenia Gravis Drugs Revenue (US$ Million) Market Share by Application (2017-2022) Table 45. Global Myasthenia Gravis Drugs Price (MT) by Application (2017-2022) Table 46. Global Myasthenia Gravis Drugs Sales (MT) by Application (2023-2028) Table 47. Global Myasthenia Gravis Drugs Sales Share by Application (2023-2028) Table 48. Global Myasthenia Gravis Drugs Revenue (US$ Million) Market Share by Application (2023-2028) Table 49. Global Myasthenia Gravis Drugs Revenue Share by Application (2023-2028) Table 50. Global Myasthenia Gravis Drugs Price (MT) by Application (2023-2028) Table 51. North America Myasthenia Gravis Drugs Sales by Company (2017-2022) & (MT) Table 52. North America Myasthenia Gravis Drugs Sales Market Share by Company (2017-2022) Table 53. North America Myasthenia Gravis Drugs Revenue by Company (2017-2022) & (US$ Million) Table 54. North America Myasthenia Gravis Drugs Revenue Market Share by Company (2017-2022) Table 55. North America Myasthenia Gravis Drugs Sales by Type (2017-2022) & (MT) Table 56. North America Myasthenia Gravis Drugs Sales by Type (2023-2028) & (MT) Table 57. North America Myasthenia Gravis Drugs Revenue by Type (2017-2022) & (US$ Million) Table 58. North America Myasthenia Gravis Drugs Revenue by Type (2023-2028) & (US$ Million) Table 59. North America Myasthenia Gravis Drugs Sales by Application (2017-2022) & (MT) Table 60. North America Myasthenia Gravis Drugs Sales by Application (2023-2028) & (MT) Table 61. North America Myasthenia Gravis Drugs Revenue by Application (2017-2022) & (US$ Million) Table 62. North America Myasthenia Gravis Drugs Revenue by Application (2023-2028) & (US$ Million) Table 63. North America Myasthenia Gravis Drugs Sales by Country (2017-2022) & (MT) Table 64. North America Myasthenia Gravis Drugs Sales by Country (2023-2028) & (MT) Table 65. North America Myasthenia Gravis Drugs Revenue by Country (2017-2022) & (US$ Million) Table 66. North America Myasthenia Gravis Drugs Revenue by Country (2023-2028) & (US$ Million) Table 67. Europe Myasthenia Gravis Drugs Sales by Company (2017-2022) & (MT) Table 68. Europe Myasthenia Gravis Drugs Sales Market Share by Company (2017-2022) Table 69. Europe Myasthenia Gravis Drugs Revenue by Company (2017-2022) & (US$ Million) Table 70. Europe Myasthenia Gravis Drugs Revenue Market Share by Company (2017-2022) Table 71. Europe Myasthenia Gravis Drugs Sales by Type (2017-2022) & (MT) Table 72. Europe Myasthenia Gravis Drugs Sales by Type (2023-2028) & (MT) Table 73. Europe Myasthenia Gravis Drugs Revenue by Type (2017-2022) & (US$ Million) Table 74. Europe Myasthenia Gravis Drugs Revenue by Type (2023-2028) & (US$ Million) Table 75. Europe Myasthenia Gravis Drugs Sales by Application (2017-2022) & (MT) Table 76. Europe Myasthenia Gravis Drugs Sales by Application (2023-2028) & (MT) Table 77. Europe Myasthenia Gravis Drugs Revenue by Application (2017-2022) & (US$ Million) Table 78. Europe Myasthenia Gravis Drugs Revenue by Application (2023-2028) & (US$ Million) Table 79. Europe Myasthenia Gravis Drugs Sales by Country (2017-2022) & (MT) Table 80. Europe Myasthenia Gravis Drugs Sales by Country (2023-2028) & (MT) Table 81. Europe Myasthenia Gravis Drugs Revenue by Country (2017-2022) & (US$ Million) Table 82. Europe Myasthenia Gravis Drugs Revenue by Country (2023-2028) & (US$ Million) Table 83. Asia Pacific Myasthenia Gravis Drugs Sales by Company (2017-2022) & (MT) Table 84. Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Company (2017-2022) Table 85. Asia Pacific Myasthenia Gravis Drugs Revenue by Company (2017-2022) & (US$ Million) Table 86. Asia Pacific Myasthenia Gravis Drugs Revenue Market Share by Company (2017-2022) Table 87. Asia Pacific Myasthenia Gravis Drugs Sales by Type (2017-2022) & (MT) Table 88. Asia Pacific Myasthenia Gravis Drugs Sales by Type (2023-2028) & (MT) Table 89. Asia Pacific Myasthenia Gravis Drugs Revenue by Type (2017-2022) & (US$ Million) Table 90. Asia Pacific Myasthenia Gravis Drugs Revenue by Type (2023-2028) & (US$ Million) Table 91. Asia Pacific Myasthenia Gravis Drugs Sales by Application (2017-2022) & (MT) Table 92. Asia Pacific Myasthenia Gravis Drugs Sales by Application (2023-2028) & (MT) Table 93. Asia Pacific Myasthenia Gravis Drugs Revenue by Application (2017-2022) & (US$ Million) Table 94. Asia Pacific Myasthenia Gravis Drugs Revenue by Application (2023-2028) & (US$ Million) Table 95. Asia Pacific Myasthenia Gravis Drugs Sales by Region (2017-2022) & (MT) Table 96. Asia Pacific Myasthenia Gravis Drugs Sales by Region (2023-2028) & (MT) Table 97. Asia Pacific Myasthenia Gravis Drugs Revenue by Region (2017-2022) & (US$ Million) Table 98. Asia Pacific Myasthenia Gravis Drugs Revenue by Region (2023-2028) & (US$ Million) Table 99. Latin America Myasthenia Gravis Drugs Sales by Company (2017-2022) & (MT) Table 100. Latin America Myasthenia Gravis Drugs Sales Market Share by Company (2017-2022) Table 101. Latin America Myasthenia Gravis Drugs Revenue by Company (2017-2022) & (US$ Million) Table 102. Latin America Myasthenia Gravis Drugs Revenue Market Share by Company (2017-2022) Table 103. Latin America Myasthenia Gravis Drugs Sales by Type (2017-2022) & (MT) Table 104. Latin America Myasthenia Gravis Drugs Sales by Type (2023-2028) & (MT) Table 105. Latin America Myasthenia Gravis Drugs Revenue by Type (2017-2022) & (US$ Million) Table 106. Latin America Myasthenia Gravis Drugs Revenue by Type (2023-2028) & (US$ Million) Table 107. Latin America Myasthenia Gravis Drugs Sales by Application (2017-2022) & (MT) Table 108. Latin America Myasthenia Gravis Drugs Sales by Application (2023-2028) & (MT) Table 109. Latin America Myasthenia Gravis Drugs Revenue by Application (2017-2022) & (US$ Million) Table 110. Latin America Myasthenia Gravis Drugs Revenue by Application (2023-2028) & (US$ Million) Table 111. Latin America Myasthenia Gravis Drugs Sales by Country (2017-2022) & (MT) Table 112. Latin America Myasthenia Gravis Drugs Sales by Country (2023-2028) & (MT) Table 113. Latin America Myasthenia Gravis Drugs Revenue by Country (2017-2022) & (US$ Million) Table 114. Latin America Myasthenia Gravis Drugs Revenue by Country (2023-2028) & (US$ Million) Table 115. Middle East and Africa Myasthenia Gravis Drugs Sales by Company (2017-2022) & (MT) Table 116. Middle East and Africa Myasthenia Gravis Drugs Sales Market Share by Company (2017-2022) Table 117. Middle East and Africa Myasthenia Gravis Drugs Revenue by Company (2017-2022) & (US$ Million) Table 118. Middle East and Africa Myasthenia Gravis Drugs Revenue Market Share by Company (2017-2022) Table 119. Middle East and Africa Myasthenia Gravis Drugs Sales by Type (2017-2022) & (MT) Table 120. Middle East and Africa Myasthenia Gravis Drugs Sales by Type (2023-2028) & (MT) Table 121. Middle East and Africa Myasthenia Gravis Drugs Revenue by Type (2017-2022) & (US$ Million) Table 122. Middle East and Africa Myasthenia Gravis Drugs Revenue by Type (2023-2028) & (US$ Million) Table 123. Middle East and Africa Myasthenia Gravis Drugs Sales by Application (2017-2022) & (MT) Table 124. Middle East and Africa Myasthenia Gravis Drugs Sales by Application (2023-2028) & (MT) Table 125. Middle East and Africa Myasthenia Gravis Drugs Revenue by Application (2017-2022) & (US$ Million) Table 126. Middle East and Africa Myasthenia Gravis Drugs Revenue by Application (2023-2028) & (US$ Million) Table 127. Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2017-2022) & (MT) Table 128. Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2023-2028) & (MT) Table 129. Middle East and Africa Myasthenia Gravis Drugs Revenue by Country (2017-2022) & (US$ Million) Table 130. Middle East and Africa Myasthenia Gravis Drugs Revenue by Country (2023-2028) & (US$ Million) Table 131. Flamel Technologies Corporation Information Table 132. Flamel Technologies Description and Overview Table 133. Flamel Technologies Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 134. Flamel Technologies Myasthenia Gravis Drugs Product and Services Table 135. Flamel Technologies Myasthenia Gravis Drugs SWOT Analysis Table 136. Flamel Technologies Recent Developments Table 137. F. Hoffmann-La Roche Corporation Information Table 138. F. Hoffmann-La Roche Description and Overview Table 139. F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 140. F. Hoffmann-La Roche Myasthenia Gravis Drugs Product and Services Table 141. F. Hoffmann-La Roche Myasthenia Gravis Drugs SWOT Analysis Table 142. F. Hoffmann-La Roche Recent Developments Table 143. Grifols Corporation Information Table 144. Grifols Description and Overview Table 145. Grifols Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 146. Grifols Myasthenia Gravis Drugs Product and Services Table 147. Grifols Myasthenia Gravis Drugs SWOT Analysis Table 148. Grifols Recent Developments Table 149. Pfizer Corporation Information Table 150. Pfizer Description and Overview Table 151. Pfizer Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 152. Pfizer Myasthenia Gravis Drugs Product and Services Table 153. Pfizer Myasthenia Gravis Drugs SWOT Analysis Table 154. Pfizer Recent Developments Table 155. Takeda Corporation Information Table 156. Takeda Description and Overview Table 157. Takeda Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 158. Takeda Myasthenia Gravis Drugs Product and Services Table 159. Takeda Myasthenia Gravis Drugs SWOT Analysis Table 160. Takeda Recent Developments Table 161. Novartis Corporation Information Table 162. Novartis Description and Overview Table 163. Novartis Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 164. Novartis Myasthenia Gravis Drugs Product and Services Table 165. Novartis Myasthenia Gravis Drugs SWOT Analysis Table 166. Novartis Recent Developments Table 167. Bausch Health Corporation Information Table 168. Bausch Health Description and Overview Table 169. Bausch Health Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 170. Bausch Health Myasthenia Gravis Drugs Product and Services Table 171. Bausch Health Myasthenia Gravis Drugs SWOT Analysis Table 172. Bausch Health Recent Developments Table 173. Alexion Pharmaceuticals Corporation Information Table 174. Alexion Pharmaceuticals Description and Overview Table 175. Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 176. Alexion Pharmaceuticals Myasthenia Gravis Drugs Product and Services Table 177. Alexion Pharmaceuticals Myasthenia Gravis Drugs SWOT Analysis Table 178. Alexion Pharmaceuticals Recent Developments Table 179. Catalyst Pharmaceuticals Corporation Information Table 180. Catalyst Pharmaceuticals Description and Overview Table 181. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 182. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Product and Services Table 183. Catalyst Pharmaceuticals Myasthenia Gravis Drugs SWOT Analysis Table 184. Catalyst Pharmaceuticals Recent Developments Table 185. CSL Corporation Information Table 186. CSL Description and Overview Table 187. CSL Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 188. CSL Myasthenia Gravis Drugs Product and Services Table 189. CSL Myasthenia Gravis Drugs SWOT Analysis Table 190. CSL Recent Developments Table 191. Curavac Corporation Information Table 192. Curavac Description and Overview Table 193. Curavac Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 194. Curavac Myasthenia Gravis Drugs Product and Services Table 195. Curavac Recent Developments Table 196. Cytokinetics Corporation Information Table 197. Cytokinetics Description and Overview Table 198. Cytokinetics Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 199. Cytokinetics Myasthenia Gravis Drugs Product and Services Table 200. Cytokinetics Recent Developments Table 201. Galencia Corporation Information Table 202. Galencia Description and Overview Table 203. Galencia Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 204. Galencia Myasthenia Gravis Drugs Product and Services Table 205. Galencia Recent Developments Table 206. GlaxoSmithKline Corporation Information Table 207. GlaxoSmithKline Description and Overview Table 208. GlaxoSmithKline Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 209. GlaxoSmithKline Myasthenia Gravis Drugs Product and Services Table 210. GlaxoSmithKline Recent Developments Table 211. Lupin Pharmaceuticals Corporation Information Table 212. Lupin Pharmaceuticals Description and Overview Table 213. Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 214. Lupin Pharmaceuticals Myasthenia Gravis Drugs Product and Services Table 215. Lupin Pharmaceuticals Recent Developments Table 216. Mitsubishi Tanabe Pharma Corporation Information Table 217. Mitsubishi Tanabe Pharma Description and Overview Table 218. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022) Table 219. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product and Services Table 220. Mitsubishi Tanabe Pharma Recent Developments Table 221. Key Raw Materials Lists Table 222. Raw Materials Key Suppliers Lists Table 223. Myasthenia Gravis Drugs Distributors List Table 224. Myasthenia Gravis Drugs Customers List Table 225. Research Programs/Design for This Report Table 226. Key Data Information from Secondary Sources Table 227. Key Data Information from Primary Sources List of Figures Figure 1. Myasthenia Gravis Drugs Product Picture Figure 2. Global Myasthenia Gravis Drugs Sales Market Share by Type in 2021 & 2028 Figure 3. Anticholinesterases Product Picture Figure 4. Immunosuppressants Product Picture Figure 5. Intravenous Immune Globulins Product Picture Figure 6. Global Myasthenia Gravis Drugs Sales Market Share by Application in 2021 & 2028 Figure 7. Hospitals Use Case Figure 8. Clinics Use Case Figure 9. Myasthenia Gravis Drugs Report Years Considered Figure 10. Global Myasthenia Gravis Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 11. Global Myasthenia Gravis Drugs Market Size 2017-2028 (US$ Million) Figure 12. Global Myasthenia Gravis Drugs Sales (2017-2022) & (MT) Figure 13. Global Myasthenia Gravis Drugs Market Size Market Share by Region: 2021 VS 2028 Figure 14. Global Myasthenia Gravis Drugs Sales Market Share by Region (2017-2022) Figure 15. Global Myasthenia Gravis Drugs Sales Market Share by Region in 2021 Figure 16. Global Myasthenia Gravis Drugs Revenue Market Share by Region in 2017 VS 2021 Figure 17. Global Myasthenia Gravis Drugs Sales Share by Manufacturers in 2021 Figure 18. The 5 and 10 Largest Manufacturers in the World: Market Share by Myasthenia Gravis Drugs Sales in 2021 Figure 19. Myasthenia Gravis Drugs Revenue Share by Manufacturers in 2021 Figure 20. Myasthenia Gravis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021 Figure 21. Global Myasthenia Gravis Drugs Revenue Share by Type (2017-2022) Figure 22. Global Myasthenia Gravis Drugs Revenue Growth Rate by Type in 2017 & 2021 Figure 23. Global Myasthenia Gravis Drugs Revenue Share by Application (2017-2022) Figure 24. Global Myasthenia Gravis Drugs Revenue Growth Rate by Application in 2017 & 2021 Figure 25. North America Myasthenia Gravis Drugs Sales Market Share by Type (2017-2028) Figure 26. North America Myasthenia Gravis Drugs Revenue Market Share by Type (2017-2028) Figure 27. North America Myasthenia Gravis Drugs Sales Market Share by Application (2017-2028) Figure 28. North America Myasthenia Gravis Drugs Revenue Market Share by Application (2017-2028) Figure 29. North America Myasthenia Gravis Drugs Sales Share by Country (2017-2028) Figure 30. North America Myasthenia Gravis Drugs Revenue Share by Country (2017-2028) Figure 31. U.S. Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 32. Canada Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 33. Europe Myasthenia Gravis Drugs Sales Market Share by Type (2017-2028) Figure 34. Europe Myasthenia Gravis Drugs Revenue Market Share by Type (2017-2028) Figure 35. Europe Myasthenia Gravis Drugs Sales Market Share by Application (2017-2028) Figure 36. Europe Myasthenia Gravis Drugs Revenue Market Share by Application (2017-2028) Figure 37. Europe Myasthenia Gravis Drugs Sales Share by Country (2017-2028) Figure 38. Europe Myasthenia Gravis Drugs Revenue Share by Country (2017-2028) Figure 39. Germany Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 40. France Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 41. U.K. Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 42. Italy Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 43. Russia Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 44. Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Type (2017-2028) Figure 45. Asia Pacific Myasthenia Gravis Drugs Revenue Market Share by Type (2017-2028) Figure 46. Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Application (2017-2028) Figure 47. Asia Pacific Myasthenia Gravis Drugs Revenue Market Share by Application (2017-2028) Figure 48. Asia Pacific Myasthenia Gravis Drugs Sales Share by Region (2017-2028) Figure 49. Asia Pacific Myasthenia Gravis Drugs Revenue Share by Region (2017-2028) Figure 50. China Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 51. Japan Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 52. South Korea Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 53. India Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 54. Australia Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 55. Taiwan Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 56. Indonesia Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 57. Thailand Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 58. Malaysia Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 59. Philippines Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 60. Vietnam Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 61. Latin America Myasthenia Gravis Drugs Sales Market Share by Type (2017-2028) Figure 62. Latin America Myasthenia Gravis Drugs Revenue Market Share by Type (2017-2028) Figure 63. Latin America Myasthenia Gravis Drugs Sales Market Share by Application (2017-2028) Figure 64. Latin America Myasthenia Gravis Drugs Revenue Market Share by Application (2017-2028) Figure 65. Latin America Myasthenia Gravis Drugs Sales Share by Country (2017-2028) Figure 66. Latin America Myasthenia Gravis Drugs Revenue Share by Country (2017-2028) Figure 67. Mexico Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 68. Brazil Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 69. Argentina Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 70. Middle East and Africa Myasthenia Gravis Drugs Sales Market Share by Type (2017-2028) Figure 71. Middle East and Africa Myasthenia Gravis Drugs Revenue Market Share by Type (2017-2028) Figure 72. Middle East and Africa Myasthenia Gravis Drugs Sales Market Share by Application (2017-2028) Figure 73. Middle East and Africa Myasthenia Gravis Drugs Revenue Market Share by Application (2017-2028) Figure 74. Middle East and Africa Myasthenia Gravis Drugs Sales Share by Country (2017-2028) Figure 75. Middle East and Africa Myasthenia Gravis Drugs Revenue Share by Country (2017-2028) Figure 76. Turkey Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 77. Saudi Arabia Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 78. U.A.E Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million) Figure 79. Myasthenia Gravis Drugs Value Chain Figure 80. Myasthenia Gravis Drugs Production Process Figure 81. Channels of Distribution Figure 82. Distributors Profiles Figure 83. Bottom-up and Top-down Approaches for This Report Figure 84. Data Triangulation Figure 85. Key Executives Interviewed

Flamel Technologies F. Hoffmann-La Roche Grifols Pfizer Takeda Novartis Bausch Health Alexion Pharmaceuticals Catalyst Pharmaceuticals CSL Curavac Cytokinetics Galencia GlaxoSmithKline Lupin Pharmaceuticals Mitsubishi Tanabe Pharma